Israel/USA: Collaboration Agreement Collaboration to Advance the Development of Breakthrough Cell and Gene Therapies
Global biotech company Orgenesis announced a collaboration agreement with Tel Aviv Sourasky Medical Center to advance Point-of-Care development and commercialization of cell and gene and therapies.
Germantown/USA — Orgenesis has entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.
Under the agreement, the parties plan to conduct collaborative cell-based research projects, initially focused on advancing the clinical development and validation of Orgenesis’ CD19 CAR-T therapies, including CAR-T derived exosome products, utilizing Orgenesis’ proprietary T-cell culturing and point-of-care processes and systems. The parties also plan to deploy Orgenesis Mobile Processing Units and Labs (“Ompuls”) onsite to support joint research and validation activities for advanced cell and gene therapies developed by both Orgenesis and the Tel Aviv Sourasky Medical Center. Ompuls are multi-purpose, mobile, autonomous good manufacturing practice (GMP) facilities designed to significantly reduce the costs of advanced therapy production and accelerate the clinical development process at the point of care.